Wilson Therapeutics AB (publ) Interim Report January 1–September 30, 2017
July 1 – September 30, 2017
- Net sales amounted to SEK 0.0 M (0.0)
- Loss for the period was SEK 29.4 M (loss: 31.9)
- Loss per share, before and after dilution, totaled SEK 1.14 (loss: 1,24)
- At September 30, cash and cash equivalents amounted to SEK 277.1 M (416.5)
January 1 – September 30, 2017
- Net sales amounted to SEK 0.0 M (0.0)
- Loss for the period was SEK 115.4 M (loss: 81.1)
- Loss per share, before and after dilution, totaled SEK 4.49 (loss: 5.81)
Significant events during the period January 1 – September 30, 2017
- Extraordinary general meeting was held in January 2017 and resolved to implement the long-term incentive program LTIP 2016
- Data from the successfully completed Phase 2 trial were presented at major scientific conferences
- Board strengthened by the appointments of Dr. Birgitte Volck and Dr. Björn Odlander
- The AGM resolved to implement the long-term incentive program LTIP 2017
- US Orphan Drug Designation granted for WTX101 for the treatment of ALS
Significant events after the end of the reporting period
- Phase 2 data published in The Lancet Gastroenterology & Hepatology
- Preliminary long-term data from the extension phase of the Phase 2 study presented at scientific conference
- Agreement reached with the FDA and EMA to initiate pivotal Phase 3 FOCuS study
”We are excited to move WTX101 into the pivotal phase of development and initiate the first global, randomized, controlled, multi-center study ever conducted in Wilson Disease. The first patient is expected to be enrolled in the Phase 3 FOCuS study in early 2018.”
Jonas Hansson, CEO of Wilson Therapeutics
Invitation to telephone conference
All interested parties are invited to participate in a web-cast telephone conference regarding the report today November 23 at 10:00 CET. The live webcast and a recorded on-demand version including the presentation material will be accessible at: https://tv.streamfabriken.com/wilson-therapeutics-q3-2017. Questions can be asked in writing via the webcast or verbally via the conference call.
To participate in the conference call, please call one of the following numbers:
- SE: +46 8 566 426 90
- UK: +44 203 008 9801
- US: +1 855 753 2235
The presentation material will also be published before the conference starts on Wilson Therapeutics’ website www.wilsontherapeutics.com under Media & Investors/ Presentations. The webcast, and later the recorded version of the webcast and the conference call, will also be accessible via Wilson Therapeutics’ website.
About Wilson Therapeutics
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics’ lead product, WTX101, is in development as a novel treatment for Wilson Disease. A Phase 2 clinical study has been successfully completed and preparations for a pivotal Phase 3 study are ongoing. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.
Visit www.wilsontherapeutics.com for more information
For further information contact:
Jonas Hansson, CEO, Wilson Therapeutics AB
Telephone: +46 8 796 00 00
Email: jonas.hansson@wtx.se
Wilson Therapeutics AB (publ)
Corp. Reg. No. 556893-0357
Kungsgatan 3
SE-111 43 Stockholm
The information in the interim report is information that Wilson Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on November 23, 2017.
This release was sent by Cision
The full report (PDF) |
Source: Wilson Therapeutics
